Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Liraglutide Actions on the Liver
NCT02198209Phase 4Withdrawn
- Sponsor
- Cedars-Sinai Medical Center
- Start
- Dec 2019
- Primary completion
- Jul 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of liraglutide in type 2 diabetes mellitus (T2DM), sponsored by Cedars-Sinai Medical Center. Primary endpoints: Liver glucokinase activity (acute effect) at 1 week and Liver glucokinase activity (chronic effect) at 6 weeks. Planned start Dec 2019; status: withdrawn.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02198209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02198209.